Clinical Trial

Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI

Study acronym: mpMRI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
Trial Details
NCT Number NCT07202845
Lead Sponsor Assiut University
Conditions MIBC, mpMRI, NAC
Enrollment 39 participants
Start Date 2025-08-29
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-02